Spironolactone increases serum uric acid levels in patients with chronic kidney disease

Journal of Human Hypertension

Volumn 28, Issue 3, 2014, Pages 210-211

  Cabrera, S E ^a   Edwards, N C ^b   Steeds, R P ^b   Townend, J N ^b   Ferro, C J ^b  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; SPIRONOLACTONE; URIC ACID;

BLOOD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

DIURETICS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME; URIC ACID;

EID: 84894038139     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.66     Document Type: Article

References (13)

1. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359(17):1811-1821.
2. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. JACC 2009;54(6):505-512.
3. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979;25(1):33-42.
4. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand 1983;213(1):27-30.
5. Shibutani Y, Ueo T, Takahashi S, Moriwaki Y, Yamamoto T. Effect of ACTH on renal excretion of purine bases in a patient with isolated ACTH deficiency. Clin Chim Acta 2000;294(1-2):185-192.
6. Namba M, Kikuchi K, Komura H, Suzuki S, Satoh N, Ohtomo T et al. Study on uric acid metabolism in patients with primary aldosteronism. Nihon Naibunpi Gakkai Zasshi 1992;68(1):51-61.
7. Anzai N, Endou H. Urate transporters: an evolving field. Semin Nephrol 2011;31(5):400-409.
8. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem 2004;279(44):45942-45950.
9. Lamprecht G, Hsieh C-J, Lissner S, Nold L, Heil A, Gaco V et al. Intestinal anion exchanger down-regulated in adenoma (DRA) is inhibited by intracellular calcium. J Biol Chem 2009;284(284):19744-19753.
10. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J AmSoc Nephrol 2012;23(12):1917-1928.
11. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension 2011;58(1):2-7.
12. Dhaun N, Webb DJ. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2012;59(1):e1.
13. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007;27(5):435-440.